Similarly, Taranu et al. [64] examined 182 MDD Caucasian patients treated with venlafaxine from the METADAP study, evaluating CYP2C19 *2, *3, *4, *5, and *17 polymorphisms. This evidence concerns the gene CYP2C19 and major depressive disorder.